MTIP
CLDX icon

Magee Thomson Investment Partners’s Celldex Therapeutics CLDX Stock Holding History

Magee Thomson Investment Partners’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-143
Closed -$39K – 105
2014
Q4 		$39K Hold
143
– – 0.01% 95
2014
Q3 		$28K Hold
143
– – 0.01% 96
2014
Q2 		$35K Hold
143
– – 0.01% 97
2014
Q1 		$38K Hold
143
– – 0.01% 97
2013
Q4 		$52K Hold
143
– – 0.01% 95
2013
Q3 		$75K Buy
+143
New +$49K 0.02% 87

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Magee Thomson Investment Partners's CLDX Position: Q1 2015 in Review

Magee Thomson Investment Partners sold out of Celldex Therapeutics (CLDX) in Q1 2015, closing a stake of 143 shares — an estimated $39K sold.

Magee Thomson Investment Partners first reported a position in CLDX in Q3 2013 and held it in 6 quarters. The position peaked at $75K in Q3 2013. 193 funds tracked by Wall St. Rank hold CLDX as of Q1 2015.

  • Magee Thomson Investment Partners reported no remaining Celldex Therapeutics position as of Q1 2015 after selling out during the quarter.
  • Magee Thomson Investment Partners sold 143 Celldex Therapeutics shares in Q1 2015, an estimated $39K.
  • Magee Thomson Investment Partners first reported a position in Celldex Therapeutics in Q3 2013 and held it in 6 quarters.
  • Magee Thomson Investment Partners's Celldex Therapeutics position peaked at $75K in Q3 2013.
  • 193 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2015.

Based on Magee Thomson Investment Partners's 13F filing for Q1 2015, filed 4 May 2015.